Clinical Trials

26/003 PHARAOH-A

PHARAOH-A: A PHase 2 trial of sAvolitnib plus osimeRtinib in MET-amplified EGFR mutant NSCLC following progression on Osimertinib And cHemotherapy

Status:

In Start-up

Summary:

PHARAOH-A will determine the efficacy and tolerability of the combination of savolitinib and osimertinib in patients with EGFR-mutated, MET-overexpressed and/or amplified advanced NSCLC following disease progression on first- or second-line osimertinib. The primary endpoint is objective tumour response rate (RECIST 1.1), with ctDNA dynamics and clearance to be examined in correlative studies. Patients with untreated and asymptomatic brain metastases can be included in the study. The study will also open to recruitment in Taiwan with first patient in expected in 2027.

Clinical trial design:

International, multi-centre, single arm, Phase 2 study

Indication:

EGFR-mutated, MET-overexpressed and/or amplified advanced NSCLC

Intervention:

Savolitinib 300 mg b.i.d. plus osimertinib 80 mg o.d. in continuous 28-day cycles

More information:

Contact: pharaoh.study@sydney.edu.au

More Clinical Trials

In Start-up:

In Start-up

24/012 DEFIANT

DEFIANT aims to determine whether Dato-DXd can provide meaningful and tolerable disease control for patients with EGFR exon 20 insertion NSCLC after progression on targeted therapy and chemotherapy, including prior amivantimab. The primary endpoint is objective tumour response rate (RECIST 1.1), with ctDNA dynamics and clearance to be examined in correlative studies. Patients with untreated and asymptomatic brain metastases can be included in the study. Due to open to recruitment in 2027.

In Start-up

PRIME-Lung

The primary aim of this clinical trial is to evaluate whether radiotherapy delivered prior to standard treatment improves overall survival in patients with metastatic non-small cell lung cancer (NSCLC). The hypothesis is that early, highly targeted radiotherapy may reduce the risk of further metastatic spread, thereby improving survival outcomes. Similar interventions have shown event-free survival benefits in lung, prostate, and nasopharyngeal cancer trials. The trial builds on PRIME-Lung-pilot with 40 patients, which demonstrated that the intervention is safe and well-tolerated. Based on these findings, the trial will now expand to include more sites and a larger patient cohort.

Join our community – stay up to date with the latest research, TOGA news and events

The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Contact

PO Box 1103
Thornbury VIC 3071
Ph: +61 3 9087 3550
ABN: 47 641 984 198

TOGA

Quicklinks

Thoracic Oncology Group of Australasia is registered with the Australian Taxation Office as an Income Tax Exempt Charitable Entity. Donations $2 and over are tax deductible.